Olmesartan Medoxomil is an AT1 subtype selected angiotensin-II receptor antagonist approved for the treatment of hypertension. It has low water solubility, so the current effort is being made to enhance the solubility of the Olmesartan by inclusion complex and to incorporate them into tablets by direct compression. Complexing agent like Beta cyclodextrin and polyvinyalpyrrolidone has been used for complexation method. FT-IR studies have shown that there is no link between drugs and complexing agents. Among all methods, the inclusion complex (OLBCD 3) containing the drug: Beta cyclodextrin in a 1: 3 ratio showed rapid drug release (87.41% within 30 minutes) and post compression parameters are within limits. All the values obtained from pre compression and post compression parameters meets the legal requirements for tablets. Stability studies of batch no OLBCD 3 shows no significant change. Therefore, it can be concluded that the structure was stable.
FT-IR Studies of Cerium Oxide Nanoparticles and Natural Zeolite Materials